Publications by authors named "Nimer Alkhatib"

Claim this Profile
E
Economic evaluation of brivaracetam in the adjunctive treatment of patients with focal-onset seizure in Jordan.
Shiraz Halloush, Nimer S Alkhatib, Osamah M Alfayez, Omar S Alkhezi, Rawan Al Froukh

Medicine (Baltimore)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appraising the cost of illness of diabetic retinopathy and diabetic macular edema over the last decade: a systematic review.
Rawaa M Jabbar, Ali Azeez Al-Jumaili, Nimer S Alkhatib, Aymen Dheyaa Jaafar

Int J Pharm Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.
Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia

PLoS One· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
Ivo Abraham, Matthias Calamia, Nimer Alkhatib, Marc Pondel, Karen MacDonald

J Med Econ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
Ivo Abraham, Matthias Calamia, Nimer Alkhatib, Marc Pondel, Karen MacDonald

J Med Econ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs.
Nimer S Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Ala'a Alkhatib, Said Alkhatib

J Med Econ· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region.
Nimer S Alkhatib, Shiraz Halloush, Ivo Abraham

Expert Opin Biol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
Shiraz Halloush, Nimer S Alkhatib, Abdulaali R Almutairi, Mathias Calamia, Hala Halawah

Ann Pharmacother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.
Hala H Halawah, Nimer S Alkhatib, Abdulaali R Almutairi, Mohammad Saleh, Shiraz S Halloush

J Med Econ· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals.
Ahmad Alamer, Abdulaali R Almutairi, Shiraz Halloush, Ahmed Al-Jedai, Ahmed Alrashed, Nimer Alkhatib

Saudi Pharm J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type.
Neda Alrawashdh, Ali McBride, Mok Oh, Nimer Alkhatib, Christopher Lee

J Adv Pract Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.
Shiraz Halloush, Abdullah A Alhifany, Nimer S Alkhatib, Abdel Qader Al Bawab, Batool Al-Qawasmeh

Curr Med Res Opin· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Arabic version of medication adherence report scale questionnaire and beliefs about medication -specific questionnaire: A factor analysis study.
Walid Al-Qerem, Abdel Qader Al Bawab, Osama Abusara, Nimer Alkhatib, Robert Horne

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective.
Nimer S Alkhatib, Abdulaali R Almutairi, Omar S Alkhezi, Osama M Alfayez, Majed S Al Yami

Saudi Pharm J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Are the Factors Associated with Nonadherence to Medications in Patients with Chronic Diseases?
Abdel Qader Al Bawab, Walid Al-Qerem, Osama Abusara, Nimer Alkhatib, Maha Mansour

Healthcare (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients.
Dina Hamarneh, Nimer Alkhatib, Kris Denhaerynck, Stefaan Vancayzeele, Heidi Brié

Curr Med Res Opin· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin injection technique in the western region of Algeria, Tlemcen.
Mohammed Nassim Boukli Hacene, Meriem Saker, Amina Youcef, Soumia Koudri, Souad Cheriet, Nimer Alkhatib

Pan Afr Med J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients.
Nimer Alkhatib, Diana Sun, Kris Denhaerynck, Dina Hamarneh, Yoleen Van Camp

Curr Med Res Opin· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ3: reference-based pricing.
Nimer S Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing.
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing.
Nimer S Alkhatib, Ali McBride, Sandipan Bhattacharjee, Kenneth Ramos, Brian Erstad

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ4: safety-based pricing.
Nimer S Alkhatib, Sandipan Bhattacharjee, Ali McBride, Kenneth Ramos, Marion Slack

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ6: adherence-based pricing.
Nimer S Alkhatib, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing.
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The six Delta platform for outcome-based contracting for pharmaceuticals.
Nimer S Alkhatib, Ivo Abraham

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis